Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Final results of the phase II AVETUX trial (AIO-KRK-0216)

被引：4
|
作者：
Stein, Alexander
Binder, Mascha
Goekkurt, Eray
Lorenzen, Sylvie
Riera-Knorrenschild, Jorge
Depenbusch, Reinhard
Ettrich, Thomas Jens
Doerfel, Steffen
Al-Batran, Salah-Eddin
Karthaus, Meinolf
Pelzer, Uwe
Simnica, Donjete
Waberer, Lisa
Hinke, Axel
Bokemeyer, Carsten
Hegewisch-Becker, Susanna
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Haematol Stem Cell Transplantat & Pneu, Hamburg, Germany
[2] Univ Med Ctr Halle Saale, Dept Internal Med 4, Halle, Germany
[3] Hematol Oncol Practice Eppendorf, Hamburg, Germany
[4] Univ Canc Ctr Hamburg, Hamburg, Germany
[5] Tech Univ Munich, Klinikum Rechts Isar, Dept Internal Med Hematol Med Oncol 3, Munich, Germany
[6] Univ Klin Marburg, Marburg, Germany
[7] Onkodok GmbH, Dedicated Res Facil, Guetersloh, Germany
[8] Ulm Univ Hosp, Ulm, Germany
[9] Onkozentrum Dresden, Dresden, Germany
[10] UCT Univ Canc Ctr, Krankenhaus Nordwest, Inst Clin Res IKF, Frankfurt, Germany
[11] Klinikum Neuperlach, Munich, Germany
[12] Charite, Berlin, Germany
[13] Univ Halle, Halle, Germany
[14] IKF GmbH Krankenhaus Nordwest, Frankfurt, Germany
[15] CCRC Canc Clin Res Consulting, Dusseldorf, Germany
[16] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[17] HOPE Hamatol Onkol Praxis Eppendorf, Hamburg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
96
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Selinexor (KPT-330), an oral Selective Inhibitor of Nuclear Export (SINE) compound, in combination with FOLFOX in patients with metastatic colorectal cancer (mCRC) - final results of the phase I SENTINEL trial
    Nilsson, S.
    Stein, A.
    Rolfo, C.
    Kranich, A.
    Quidde, J.
    Papadimitriou, K.
    Theile, S.
    Amberg, S.
    Bokemeyer, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 122 - 122
  • [42] A randomized phase II trial of mFOLFOX6-based standard of care alone or in combination with Ad-CEA vaccine plus avelumab in patients with previously untreated metastatic colorectal cancer
    Redman, J.
    Gandhy, S.
    Gatti-Mays, M.
    Sater, H. Abdul
    Tsai, Y.
    Donahue, R.
    Cordes, L.
    Steinberg, S.
    Marte, J.
    McMahon, S.
    Madan, R.
    Karzai, F.
    Bilusic, M.
    Rabizadeh, S.
    Lee, J.
    Soon-Shiong, P.
    Kim, S.
    Marshall, J.
    Weinberg, B.
    Schlom, J.
    Gulley, J.
    Strauss, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S227 - S227
  • [43] Phase II study of avelumab in combination with cetuximab as a rechallenge strategy in pre-treated RAS wild type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) colon
    Martinelli, E.
    Troiani, T.
    Cardone, C.
    Ciardiello, D.
    Zanaletti, N.
    Borrelli, C.
    Terminiello, M.
    Avallone, A.
    Falcone, A.
    Maiello, E.
    Bordonaro, R.
    Santini, D.
    Garufi, C.
    Pietrantonio, F.
    Pinto, C.
    Santabarbara, G.
    Normanno, N.
    Ciardiello, F.
    ANNALS OF ONCOLOGY, 2019, 30
  • [44] Phase II study of avelumab in combination with cetuximab in pre-treated RAS wild-type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) Colon.
    Troiani, Teresa
    Martinelli, Erika
    Ciardiello, Davide
    Zanaletti, Nicoletta
    Cardone, Claudia
    Borrelli, Carola
    Avallone, Antonio
    Falcone, Alfredo
    Maiello, Evaristo
    Bordonaro, Roberto
    Santini, Daniele
    Garufi, Carlo
    De Braud, Filippo G.
    Pinto, Carmine
    Gridelli, Cesare
    Ciardiello, Fortunato
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [45] Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer (mCRC): AIO KRK-0104 trial
    Heinemann, V.
    von Weikersthal, L. Fischer
    Vehling-Kaiser, U.
    Stauch, M.
    Hass, H.
    Dietzfelbinger, H. F.
    Oruzio, D. V.
    Klein, S.
    Zellmann, K.
    Decker, T.
    Schulze, M.
    Abenhardt, W.
    Puchtler, G.
    Kappauf, H. W.
    Mittermueller, J.
    Haberl, C.
    Giessen, C. A.
    Moosmann, N.
    Stintzing, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [46] PHASE II STUDY OF S-1 COMBINED WITH IRINOTECAN AND OXALIPLATIN (TIROX) IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (MCRC)
    Hong, Y. S.
    Kim, S. Y.
    Park, J. W.
    Lim, S.
    Choi, H. S.
    Jeong, S. Y.
    Kim, D. Y.
    Hong, C. W.
    Sohn, D. K.
    Jung, K. H.
    ANNALS OF ONCOLOGY, 2008, 19 : 136 - 136
  • [47] Phase II trial of imatinib, bevacizumab and cetuximab plus modified FOLFOX-6 in advanced untreated colorectal cancer
    Sobrero, A. F.
    Bennicelli, E.
    Pessino, A.
    Guglielmi, A.
    Mammoliti, S.
    Caprioni, F.
    Fornarini, G.
    Comandini, D.
    Sciallero, S.
    Ansaldi, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [48] CEDIRANIB plus FOLFOX/XELOX VERSUS PLACEBO plus FOLFOX/XELOX IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (MCRC): A RANDOMIZED, DOUBLE-BLIND, PHASE III STUDY (HORIZON II)
    Hoff, P. M.
    Hochhaus, A.
    Pestalozzi, B. C.
    Tebbutt, N. C.
    Li, J.
    Kim, T. W.
    Pike, L.
    Fielding, A.
    Robertson, J.
    Saunders, M. P.
    ANNALS OF ONCOLOGY, 2010, 21 : 9 - 9
  • [49] Final results from the CAVE (cetuximab rechallenge plus avelumab) mCRC phase II trial: Skin toxicity as a predictor of clinical activity.
    Martini, Giulia
    Napolitano, Stefania
    Famiglietti, Vincenzo
    De Braud, Filippo G.
    Terminiello, Marinella
    Borrelli, Carola
    Vitiello, Pietro Paolo
    Avallone, Antonio
    Normanno, Nicola
    Maiello, Evaristo
    Falcone, Alfredo
    Santabarbara, Giuseppe
    Pinto, Carmine
    Santini, Daniele
    Di Liello, Alessandra
    Renato, Daniela
    Esposito, Lucia
    Marrone, Francesca
    Troiani, Teresa
    Ciardiello, Davide
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [50] CETUXIMAB PLUS XELIRI VERSUS CETUXIMAB PLUS XELOX AS FIRST-LINE TREATMENT FOR PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC): ANALYSIS OF THE RANDOMIZED TRIAL OF THE GERMAN AIO CRC STUDY GROUP: KRK-0204
    Stintzing, S.
    Jung, A.
    Vehling-Kaiser, U.
    Stauch, M.
    Hass, H.
    Dietzfelbinger, H.
    von Weikersthal, L. Fischer
    Moosmann, N.
    Kirchner, T.
    Heinemann, V.
    ANNALS OF ONCOLOGY, 2010, 21 : 189 - 190
12345